Prakash Investment Advisors LLC Sells 1,140 Shares of Medpace Holdings, Inc. $MEDP

Prakash Investment Advisors LLC cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 65.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 610 shares of the company’s stock after selling 1,140 shares during the quarter. Prakash Investment Advisors LLC’s holdings in Medpace were worth $314,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Quent Capital LLC bought a new position in Medpace in the 3rd quarter worth about $25,000. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Employees Retirement System of Texas purchased a new position in Medpace during the second quarter valued at approximately $36,000. Root Financial Partners LLC purchased a new position in Medpace during the third quarter valued at approximately $38,000. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in Medpace by 35.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after acquiring an additional 27 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 201,745 shares of company stock valued at $122,369,738 in the last three months. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on MEDP. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a research report on Friday, February 13th. Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a report on Tuesday, February 10th. Truist Financial decreased their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Finally, Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $483.45.

Medpace Stock Performance

MEDP stock opened at $446.44 on Friday. The firm has a market cap of $12.67 billion, a P/E ratio of 29.18, a P/E/G ratio of 2.14 and a beta of 1.42. The firm’s fifty day moving average is $558.09 and its 200 day moving average is $537.81. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s revenue was up 32.0% on a year-over-year basis. During the same period in the prior year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.